Alnylam Pharmaceuticals, Inc. (ALNY)
After hours:
Chart Events
Performance Outlook
| Previous Close | 231.59 |
| Open | 231.59 |
| Bid | 223.20 x 1000 |
| Ask | 232.00 x 800 |
| Day's Range | 225.52 - 232.20 |
| 52 Week Range | 117.58 - 242.97 |
| Volume | |
| Avg. Volume | 742,493 |
| Market Cap | 27.672B |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.55 |
| Earnings Date | Feb 08, 2023 - Feb 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 239.09 |
- Zacks
Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22
Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.
- Business Wire
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
CAMBRIDGE, Mass., January 08, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches.
- Motley Fool
3 Growth Stocks That Could Rocket Higher in 2023
If you're looking for stocks that can make dramatic gains quickly, it's hard to do any better than the biotechnology industry. Hardly a week goes by without at least one biotech stock shooting higher or tumbling lower in response to exciting news about experimental treatments. In 2023, all three of these drugmakers will report study results that are awfully important to their futures.
